Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology

Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24

Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24

Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24

Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24

Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24

Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24

A Faster Tandem CAR T-Cell Product, Zamto-Cel Being Studied in DLBCL | Nirav Shah, MD, MSHP | #ASH24

A Faster Tandem CAR T-Cell Product, Zamto-Cel Being Studied in DLBCL | Nirav Shah, MD, MSHP | #ASH24

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24

Exploring Barriers to CAR T-Cell Therapy in Blood Cancer Patients | Yannis Valtis, MD | #ASH24

Exploring Barriers to CAR T-Cell Therapy in Blood Cancer Patients | Yannis Valtis, MD | #ASH24

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24

Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24

Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics

Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | Muhammad Umair Mushtaq | #ASH24

Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | Muhammad Umair Mushtaq | #ASH24